anytime hits the devils number then goes down, has always then preceded to go below it's 52 week low.
You have been suckered by the best to buy the phony rally to distribute insiders stock. Sell and short here. Good luck from the Devil Trader
I'm wondering whether the recent buying activity was a large buyer (who had presumably done their homework), or if it was a index fund that just had to buy a certain number of CRY shares.
Either way though, the devil seems to be hard at work at CRY.
SA didn't hire the devil as an employee did he?
The only way for SA to salvage his sordid stock price history is to get the stock price up substantially. History: Over $12 in 1996 and under $6 today. Factor in inflation, and the story gets worse. Right now we have 16 years of SA under performance, and the clock is still ticking.
Oh what could have been. My recollection was that a few years back the analysts were projecting EPS of $0.55 for CY2012. Logically 2013 and 2014 EPS numbers would have been still better. Instead EPS for CY2012 might hit $0.35, if we're lucky. Think of the affect this has had on the current stock price. Ouch!
IMO, all the above EPS affect was the direct result of SA's decisions. SA insisted on a win for CRY (complete take over of Medafor) and a lose position for Medafor shareholders (because of the ridiculously low offer price). Instead SA chalked up a loss for CRY's shareholders. All the while though, SA still got paid his salary (currently $1 million), plus options, plus car, plus country club membership, etc. This is yet another reason why SA has not been an effective Chairman of the Board, CEO, and President in recent years.
Also, SA instituted a dividend policy when he should have instead been using that money to buy back stock. He has made several recent investments that have largely depleted CRY's liquidity situation. The story is still out on these investments. By the second half of CY2013, at least the Hero Graft, and Revascular Technology product lines better be showing at least 6%, or higher, QoQ revenue growth. If not, they will prove to be SA mistakes as well. If CRY can grow these product lines fast enough, while at the same time maintaining strong grow margins, then these two produce lines may prove to have been prudent. Time will tell us how good, or bad, these two investments turn out.
All just my personal thoughts and opinions. Do your own due diligence.